<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04828538</url>
  </required_header>
  <id_info>
    <org_study_id>MCI102020</org_study_id>
    <nct_id>NCT04828538</nct_id>
  </id_info>
  <brief_title>Vitamin D, Omega-3, and Combination Vitamins B, C and Zinc Supplementation for the Treatment and Prevention of COVID-19</brief_title>
  <acronym>NUTROVID</acronym>
  <official_title>Prevent and Treat Double-Blind Factorial Randomized Trials of Daily Oral Vitamin D, Omega 3, and Combination Vitamins B, C and Zinc Supplementation for the Treatment and Prevention of COVID-19</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Hospital de la Soledad</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Microclinic International</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>Hospital de la Soledad</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      The NUTROVID Factorial Trials&#xD;
&#xD;
      The purpose of the NUTROVID-Prevent and NUTROVID-Treat Factorial Trials is to determine&#xD;
      whether Vitamin B Complex, Vitamin C, and Zinc; Vitamin D; and Omega3, taken at dosages&#xD;
      approximating recommended dosages, can reduce the risk of COVID-19 infection,&#xD;
      hospitalization, mortality.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Inadequate vitamin intake is common in Mexico. Vitamin deficiency is hypothesized as a risk&#xD;
      factor for COVID-19 infection and severe outcomes. Specifically, Vitamin D has been&#xD;
      hypothesized as a regulator of the inflammatory cytokine response; Vitamin C may help reduce&#xD;
      the risk of a cytokine storm and support the immune system; Vitamin B reduces&#xD;
      pro-inflammatory cytokine levels, helps improve respiratory function, reduces&#xD;
      hypercoagulability, and promotes endothelial structural integrity; Resolvins, derived from&#xD;
      Omega3s, are a type of specialized pro-resolving lipid autacoid mediators hypothesized to&#xD;
      prevent cytokine storms. Elemental Zinc is hypothesized to inhibit the replication of&#xD;
      viruses.&#xD;
&#xD;
      The NUTROVID-Prevent and NUTROVID-Treat Factorial Trials are testing the efficacy of these&#xD;
      supplements (Vitamins B, C, D, Zinc, and Omega 3) when used over a 60 day period among those&#xD;
      who test positive (Treat) and negative (Prevent) for SARS-COV-2 via a PCR test.&#xD;
&#xD;
      The NUTROVID Trials utilize an innovative and cost-efficient approach, leveraging the&#xD;
      existing infrastructure of the hospital system in San Luis Potosí province of Mexico. For&#xD;
      NUTROVID-Treat, we aim to enroll ~1,800 adults who have recently tested positive for&#xD;
      SARS-Cov-2 and who have given informed consent. These ~1,800 adult females and males age 18&#xD;
      or older will be enrolled and randomized into the NUTROVID Treat Factorial Trial's 2x2x2&#xD;
      arms, in which 50% of the population will have a chance to receive any combination of the 3&#xD;
      supplement formulations; the other 50% will receive the respective placebos.&#xD;
&#xD;
      Those who test negative will be randomized into the NUTROVID-Prevent Factorial Trial's 2x2x2&#xD;
      arms, in which 50% of the population will have a chance to receive any combination of the 3&#xD;
      supplement formulations; the other 50% will receive the respective placebos. For&#xD;
      NUTROVID-Prevent, we also aim to recruit ~1,800 adults, females and males.&#xD;
&#xD;
      Hospital staff will review medical records for vital events and conduct patient and family&#xD;
      follow-up until ~November 2021.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Active, not recruiting</overall_status>
  <start_date type="Actual">January 1, 2021</start_date>
  <completion_date type="Anticipated">November 30, 2021</completion_date>
  <primary_completion_date type="Anticipated">November 30, 2021</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Factorial Assignment</intervention_model>
    <intervention_model_description>Double-blind randomized, placebo-controlled double blinded 2x2x2 factorial trials (includes 2 trials: treatment cohort and prevention cohort) of the following oral supplementation treatments for up to 60 days per person:&#xD;
Factorial 1 (F1): 4000 IU Vitamin D vs placebo Factorial 2 (F2): 1000mg Omega DHA/EPA vs. placebo Factorial 3 (F3): Combination 1000 mg Vitamin C, Vitamin B complex** and Zinc Acetate, 100 mg/day vs. placebo&#xD;
**(Vitamin B complex components: B12=1 mg; B6=50 mg; B9=2.5 mg; B1</intervention_model_description>
    <primary_purpose>Other</primary_purpose>
    <masking>Double (Participant, Care Provider)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Covid infection rate (PREVENT Trial only)</measure>
    <time_frame>30 and 60 days</time_frame>
    <description>1.a. Incidence of positive PCR at ~1 month and ~2 months; 1.b. Incidence of symptomatic positive PCR and asymptomatic positive PCR at 1 month and 2 months.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Incidence of severe outcome (TREAT Trial only)</measure>
    <time_frame>1.a. 1-30 days; 1.b. 30-60; 1.c. 30 days to ~November 2021; 1.d. 60 days to ~ November 2021</time_frame>
    <description>1.a. Incidence of severe outcome (mortality or ICU admission or intubation) up to 30 days.&#xD;
1.b. Incidence of severe outcome (mortality or ICU admission or intubation) from 30-60 days.&#xD;
1.c. Incidence of severe outcome (mortality or ICU admission or intubation), from 30 days to ~ November 2021.&#xD;
1.d. Incidence of severe outcome (mortality or ICU admission or intubation), from 60 days to&#xD;
~ November 2021.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Incidence of hospitalization and death (PREVENT Trial only)</measure>
    <time_frame>1-10 months</time_frame>
    <description>2.a. Incidence of hospitalization, follow-up to ~ November 2021. 2.b. Incidence of severe outcome (mortality or ICU admission or intubation), follow-up to ~November 2021.&#xD;
2.c. Incidence of death, follow-up to ~November 2021.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Length of hospitalization and death after discharge (TREAT Trial only)</measure>
    <time_frame>2.a. 1-30 days; 2.b. 1 day(s) to ~November 2021, 2.c. 30 days to ~November 2021</time_frame>
    <description>2.a. Length of hospitalization for admissions less than 30 days from baseline versus for admissions after 30 days from baseline. 2.b. [If available] Incidence of hospital readmission after discharge, follow-up to ~November 2021.&#xD;
2.c. Incidence of death after discharge, follow-up to ~November 2021.</description>
  </secondary_outcome>
  <other_outcome>
    <measure>Changes in HbA1c (PREVENT Trial only)</measure>
    <time_frame>1-30; 1-60 days</time_frame>
    <description>Change in HbA1c at 1 month and 2 months</description>
  </other_outcome>
  <other_outcome>
    <measure>Change in diabetes status (PREVENT Trial only)</measure>
    <time_frame>1-30; 1-60 days</time_frame>
    <description>Change in diabetes status at 1 month and 2 months</description>
  </other_outcome>
  <other_outcome>
    <measure>Change in weight (PREVENT Trial only)</measure>
    <time_frame>1-30; 1-60 days</time_frame>
    <description>Change in weight at 1 month and 2 months</description>
  </other_outcome>
  <other_outcome>
    <measure>Incidence of COVID -19 symptoms at 1 month and 2 months (PREVENT Trial only)</measure>
    <time_frame>1-30; 1-60 days</time_frame>
    <description>[If available] Incidence of COVID -19 symptoms at 1 month and 2 months</description>
  </other_outcome>
  <other_outcome>
    <measure>Incidence of hospital readmission (PREVENT Trial only)</measure>
    <time_frame>1-30; 1-60 days; 1 day to ~November 2021</time_frame>
    <description>[If available] Incidence of COVID -19 symptoms at 1 month and 2 months with follow-up to ~November 2021</description>
  </other_outcome>
  <other_outcome>
    <measure>Incidence of ICU admission (PREVENT Trial only)</measure>
    <time_frame>1-30; 1-60 days; 1 day to ~November 2021</time_frame>
    <description>[If available] Incidence of ICU admission (PREVENT Trial only)</description>
  </other_outcome>
  <other_outcome>
    <measure>Incidence of intubation (PREVENT Trial only)</measure>
    <time_frame>1-30; 1-60 days; 1 day to ~November 2021</time_frame>
    <description>[If available] Incidence of intubation (PREVENT Trial only)</description>
  </other_outcome>
  <other_outcome>
    <measure>Incidence of Vaccination (PREVENT Trial only)</measure>
    <time_frame>1-30; 1-60 days; 1 day to ~November 2021</time_frame>
    <description>[If available] Incidence of vaccination</description>
  </other_outcome>
  <other_outcome>
    <measure>Change in HbA1c at 1 month and 2 months (TREAT Trial only)</measure>
    <time_frame>1-30 days and 1-60 days</time_frame>
    <description>[If available] Change in HbA1c at 1 month and 2 months.</description>
  </other_outcome>
  <other_outcome>
    <measure>Change in diabetes status at 1 month and 2 months (TREAT Trial only)</measure>
    <time_frame>1-30 days and 1-60 days</time_frame>
    <description>[If available] Change in diabetes status at 1 month and 2 months.</description>
  </other_outcome>
  <other_outcome>
    <measure>Change in weight at 1 month and 2 months (TREAT Trial only)</measure>
    <time_frame>1-30 days and 1-60 days</time_frame>
    <description>[If available] Change in weight at 1 month and 2 months</description>
  </other_outcome>
  <other_outcome>
    <measure>Incidence of COVID -19 symptoms at 1 month and 2 months (TREAT Trial only)</measure>
    <time_frame>1-30 days and 1-60 days</time_frame>
    <description>[If available] Incidence of COVID -19 symptoms at 1 month and 2 months.</description>
  </other_outcome>
  <other_outcome>
    <measure>Incidence of depression (TREAT Trial only)</measure>
    <time_frame>~1-60 days</time_frame>
    <description>[If available] Incidence of depression</description>
  </other_outcome>
  <other_outcome>
    <measure>Incidence of vaccination (TREAT Trial only)</measure>
    <time_frame>1-30; 1-60 days; 1 day to ~November 2021</time_frame>
    <description>[If available] Incidence of vaccination</description>
  </other_outcome>
  <other_outcome>
    <measure>Incidence of vaccine hesitancy (TREAT Trial only)</measure>
    <time_frame>~1-60 days</time_frame>
    <description>[If available] Incidence of vaccine hesitancy</description>
  </other_outcome>
  <other_outcome>
    <measure>ICU readmission (TREAT Trial only)</measure>
    <time_frame>1-30; 1-60 days; 1 day to ~November 2021</time_frame>
    <description>[If available] ICU readmission</description>
  </other_outcome>
  <other_outcome>
    <measure>Incidence of Intubation (upon readmission) (TREAT Trial only)</measure>
    <time_frame>1-30; 1-60 days; 1 day to ~November 2021</time_frame>
    <description>[If available] Incidence of Intubation</description>
  </other_outcome>
  <number_of_arms>8</number_of_arms>
  <enrollment type="Anticipated">1800</enrollment>
  <condition>Covid19</condition>
  <arm_group>
    <arm_group_label>1 - Vitamin D, Omega 3, Vitamins B, C, Zinc</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Vitamin D of F1 Omega 3 of F2 Vitamins B, C, Zinc of F3&#xD;
[60 days]</description>
  </arm_group>
  <arm_group>
    <arm_group_label>2 - Vitamin D, Omega 3</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Vitamin D of F1 Omega 3 of F2 Placebo of F3&#xD;
[60 days]</description>
  </arm_group>
  <arm_group>
    <arm_group_label>3 - Vitamin D, Vitamins B, C, Zinc</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Vitamin D of F1 Placebo of F2 Vitamins B, C, Zinc of F3&#xD;
[60 days]</description>
  </arm_group>
  <arm_group>
    <arm_group_label>4 - Vitamin D</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Vitamin D of F1 Placebo of F2 Placebo of F3&#xD;
[60 days]</description>
  </arm_group>
  <arm_group>
    <arm_group_label>5 - Omega 3, Vitamins B, C, Zinc,</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Placebo of F1 Omega 3 of F2 Vitamins B, C, Zinc of F3&#xD;
[60 days]</description>
  </arm_group>
  <arm_group>
    <arm_group_label>6 - Omega 3</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Placebo of F1 Omega 3 of F2 Placebo of F3&#xD;
[60 days]</description>
  </arm_group>
  <arm_group>
    <arm_group_label>7 - Vitamins B, C, Zinc</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Placebo of F1 Placebo of F2 Vitamins B, C, Zinc of F3&#xD;
[60 days]</description>
  </arm_group>
  <arm_group>
    <arm_group_label>8 - No Interventions</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>Placebo of F1 Placebo of F2 Placebo of F3&#xD;
[60 days]</description>
  </arm_group>
  <intervention>
    <intervention_type>Dietary Supplement</intervention_type>
    <intervention_name>Vitamin D</intervention_name>
    <description>Daily 4000 IU Vitamin D for 60 days</description>
    <arm_group_label>1 - Vitamin D, Omega 3, Vitamins B, C, Zinc</arm_group_label>
    <arm_group_label>2 - Vitamin D, Omega 3</arm_group_label>
    <arm_group_label>3 - Vitamin D, Vitamins B, C, Zinc</arm_group_label>
    <arm_group_label>4 - Vitamin D</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Dietary Supplement</intervention_type>
    <intervention_name>Omega DHA / EPA</intervention_name>
    <description>Daily 1000mg Omega DHA/EPA for 60 days</description>
    <arm_group_label>1 - Vitamin D, Omega 3, Vitamins B, C, Zinc</arm_group_label>
    <arm_group_label>2 - Vitamin D, Omega 3</arm_group_label>
    <arm_group_label>5 - Omega 3, Vitamins B, C, Zinc,</arm_group_label>
    <arm_group_label>6 - Omega 3</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Dietary Supplement</intervention_type>
    <intervention_name>Vitamin C, Vitamin B complex and Zinc Acetate</intervention_name>
    <description>Combination 1000 mg Vitamin C, Vitamin B complex** and Zinc Acetate, 100 mg/day for 60 days&#xD;
**(Vitamin B complex components: B12=1 mg; B6=50 mg; B9=2.5 mg; B1=100 mg; B2=100 mg; B3=14 mg; B7=50 mg)</description>
    <arm_group_label>1 - Vitamin D, Omega 3, Vitamins B, C, Zinc</arm_group_label>
    <arm_group_label>3 - Vitamin D, Vitamins B, C, Zinc</arm_group_label>
    <arm_group_label>5 - Omega 3, Vitamins B, C, Zinc,</arm_group_label>
    <arm_group_label>7 - Vitamins B, C, Zinc</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>Placebo</intervention_name>
    <description>Placebo</description>
    <arm_group_label>8 - No Interventions</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Positive SARS-CoV-2 Test group (Target enrollment: N=1,800) NUTROVID Treat Trial: Adult&#xD;
        men/women recently diagnosed with COVID-19 (positive PCR test for SARS-CoV-2 coronavirus)&#xD;
        within &lt;=5 days of symptom onset; and satisfying one of these risk factors: &gt;=50 years old;&#xD;
        or Diabetic &amp; &gt;=40 years old; or Obese &amp; &gt;=40 years old.&#xD;
&#xD;
        Negative SARS-CoV-2 Test group (Target enrollment: N=1,800) NUTROVID Prevent Trial: Adult&#xD;
        men/women recently tested negative for COVID-19 (negative PCR test for SARS-CoV-2&#xD;
        coronavirus); and satisfying one of these risk factors: &gt;=50 years old; or Diabetic &amp; &gt;=40&#xD;
        years old; or Obese &amp; &gt;=40 years old.&#xD;
&#xD;
        Signed Informed Consent Form&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Patients requiring immediate intubation or deemed likely to die within 48 hours.&#xD;
&#xD;
          -  Patients deemed likely for transfer to an ICU within 48 hours.&#xD;
&#xD;
          -  Patients currently taking oral corticosteroids for any reason at the time of&#xD;
             presentation for care.&#xD;
&#xD;
          -  Patients included in any other interventional trial.&#xD;
&#xD;
          -  Uncontrolled bacterial superinfection.&#xD;
&#xD;
          -  Severe chronic kidney disease (stage 4) or requiring dialysis (i.e. eGFR &lt; 30).&#xD;
&#xD;
          -  Pregnant women or women who are breastfeeding.&#xD;
&#xD;
          -  Immunocompromised patients.&#xD;
&#xD;
          -  Any patient with recent treatment (past 30 days) of immunosuppressive agents including&#xD;
             (but not restricted to) DMARDs, corticosteroids, antibody therapy, intravenous&#xD;
             immunoglobulins etc.&#xD;
&#xD;
          -  Patients with acute myocardial infarction.&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Eric Ding, ScD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Federation of American Scientists</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Daniel E Zoughbie, DPhil</last_name>
    <role>Principal Investigator</role>
    <affiliation>Microclinic Social Network Research Group</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Diego Sanchez, MSc</last_name>
    <role>Study Director</role>
    <affiliation>Microclinic Social Network Research Group</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Hospital de Soledad</name>
      <address>
        <city>San Luis Potosí</city>
        <state>SLP</state>
        <zip>78435</zip>
        <country>Mexico</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Mexico</country>
  </location_countries>
  <reference>
    <citation>Laird E, Rhodes J, Kenny RA. Vitamin D and Inflammation: Potential Implications for Severity of Covid-19. Ir Med J. 2020 May 7;113(5):81.</citation>
    <PMID>32603576</PMID>
  </reference>
  <reference>
    <citation>Boretti A, Banik BK. Intravenous vitamin C for reduction of cytokines storm in acute respiratory distress syndrome. PharmaNutrition. 2020 Jun;12:100190. doi: 10.1016/j.phanu.2020.100190. Epub 2020 Apr 21. Review.</citation>
    <PMID>32322486</PMID>
  </reference>
  <reference>
    <citation>Panigrahy D, Gilligan MM, Huang S, Gartung A, Cortés-Puch I, Sime PJ, Phipps RP, Serhan CN, Hammock BD. Inflammation resolution: a dual-pronged approach to averting cytokine storms in COVID-19? Cancer Metastasis Rev. 2020 Jun;39(2):337-340. doi: 10.1007/s10555-020-09889-4.</citation>
    <PMID>32385712</PMID>
  </reference>
  <reference>
    <citation>Shakoor H, Feehan J, Mikkelsen K, Al Dhaheri AS, Ali HI, Platat C, Ismail LC, Stojanovska L, Apostolopoulos V. Be well: A potential role for vitamin B in COVID-19. Maturitas. 2021 Feb;144:108-111. doi: 10.1016/j.maturitas.2020.08.007. Epub 2020 Aug 15.</citation>
    <PMID>32829981</PMID>
  </reference>
  <reference>
    <citation>Entrenas Castillo M, Entrenas Costa LM, Vaquero Barrios JM, Alcalá Díaz JF, López Miranda J, Bouillon R, Quesada Gomez JM. &quot;Effect of calcifediol treatment and best available therapy versus best available therapy on intensive care unit admission and mortality among patients hospitalized for COVID-19: A pilot randomized clinical study&quot;. J Steroid Biochem Mol Biol. 2020 Oct;203:105751. doi: 10.1016/j.jsbmb.2020.105751. Epub 2020 Aug 29.</citation>
    <PMID>32871238</PMID>
  </reference>
  <reference>
    <citation>Singh M, Das RR. Zinc for the common cold. Cochrane Database Syst Rev. 2013 Jun 18;(6):CD001364. doi: 10.1002/14651858.CD001364.pub4. Review. Update in: Cochrane Database Syst Rev. 2015;(4):CD001364.</citation>
    <PMID>23775705</PMID>
  </reference>
  <verification_date>November 2021</verification_date>
  <study_first_submitted>March 12, 2021</study_first_submitted>
  <study_first_submitted_qc>March 31, 2021</study_first_submitted_qc>
  <study_first_posted type="Actual">April 2, 2021</study_first_posted>
  <last_update_submitted>November 9, 2021</last_update_submitted>
  <last_update_submitted_qc>November 9, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">November 17, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Hospital de la Soledad</investigator_affiliation>
    <investigator_full_name>Dr. Arturo Yanez</investigator_full_name>
    <investigator_title>On-site Principal Investigator</investigator_title>
  </responsible_party>
  <keyword>Covid19</keyword>
  <keyword>Nutritional supplements</keyword>
  <keyword>Vitamin B</keyword>
  <keyword>Vitamin C</keyword>
  <keyword>Elemental Zinc</keyword>
  <keyword>Cytokine storm</keyword>
  <keyword>Vitamin D</keyword>
  <keyword>Vitamin B Complex</keyword>
  <keyword>Omega 3</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>COVID-19</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Vitamin D</mesh_term>
    <mesh_term>Vitamins</mesh_term>
    <mesh_term>Ascorbic Acid</mesh_term>
    <mesh_term>Folic Acid</mesh_term>
    <mesh_term>Vitamin B Complex</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

